

INFORMATION DISCLOSURE CITATION

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

HEMAC-58977

SERIAL NO.

10/027,478

APPLICANT

JOSHUA LEVY

FILING DATE

12/21/2001

GROUP

n/a

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPLICABLE
VBD	1	4,863,730	09-05-1989	Karpas	424 86	09/19/1986

OTHER DOCUMENTS

A	Identification of the cellular receptor for anthrax toxin, Nature/Vol. 414/8 November 2001	pages not given
B	Crystal structure of the anthrax lethal factor, Nature/Vol. 414/8 November 2001	pages not given
C	Facts about Anthrax, Centers for Disease Control and Prevention, September 2001	
D	CNN.com 10 things you need to know about anthrax, October 29, 2001	(No hyperlinks allowed)
E	Techniques to identify microorganisms etc., Centers for Disease Control and Prevention, April 18, 2001	p 1-16.
F	Clinical Uses of Intravenous Immunoglobulins, © 1990 American College of Physicians	p 278-292, 412.
G	Treatment of Gram-Negative Bacteremia And Shock With Human Antiserum To A Mutant Escherichia Coli, The New England Journal of Medicine, November 11, 1982, Vol. 307, No. 20	p 1225-1230.
H	Intravenous Immunoglobulin Therapy, The American Journal of Medicine, Vol 83, October 23, 1987	p 52-56.
I	Intravenous Immune Globulin for Prevention of Cytomegalovirus Infection and Interstitial Pneumonia After Bone Marrow Transplantation, Annals of Internal Medicine, 1987	Vol. 106, p 12-18; Winston et al.
J	Intravenous Immune Globulin for the Prevention of Bacterial Infections In Children with Symptomatic Human Immunodeficiency Virus Infection, The New England Journal of Medicine, Vol. 325, July 11, 1991, No. 2	p 73-80.
K	Prophylaxis of varicella in high-risk children: Dose-response effect of zoster immune globulin, The Journal of Pediatrics, March 1981, Vol. 98, NO. 3 pp. 368-373	Orenstein et al.
L	Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant Recipients, Prevention of Cytomegalovirus Disease - Snyderman et al., Vol 317, No. 17	p 1049-1054.
M	Hepatitis B Immune Globulin (HBIG) Efficacy in the Interruption of Perinatal Transmission of Hepatitis B Virus Carrier State, The Lancet, August 22, 1981	p 388-393.
N	Search for Correlates of Protective Immunity Conferred by Anthrax Vaccine, Infection and Immunity, May 2001, pp 2888-2893	Vol. 69(5), Reuveny, S. et al.
O	Passive Protection by Polyclonal Antibodies Against Bacillus Anthracis Infection in Guinea Pigs, Infection and Immunity, Dec. 1997, pp 5171-5175	Little et al, vol. 65(12).
P	Quantitative Assays for Evaluation of HTLV-III Inactivation Procedures: Tri(n-butyl) phosphate:sodium cholate and β -Propiolactone, Cancer Research, Vol. 45 September 1985	Prince, AM et al, page 4592 St.

EXAMINER

DATE CONSIDERED

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.